114 related articles for article (PubMed ID: 33710366)
1. Moderate-severe grade of chronic graft versus host disease and younger age (less than 45 years old) are risk factors for avascular necrosis in adult patients undergoing allogeneic hematopoietic cell transplantation.
Law AD; Bhella S; Pasic I; Lam W; Michelis FV; Gerbitz A; Viswabandya A; Kumar R; Lipton JH; Mattsson J; Kim DDH
Ann Hematol; 2021 May; 100(5):1311-1319. PubMed ID: 33710366
[TBL] [Abstract][Full Text] [Related]
2. Avascular osteonecrosis after allogeneic hematopoietic stem-cell transplantation: diagnosis and gender matter.
Schulte CM; Beelen DW
Transplantation; 2004 Oct; 78(7):1055-63. PubMed ID: 15480174
[TBL] [Abstract][Full Text] [Related]
3. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents.
Li X; Brazauskas R; Wang Z; Al-Seraihy A; Baker KS; Cahn JY; Frangoul HA; Gajewski JL; Hale GA; Hsu JW; Kamble RT; Lazarus HM; Marks DI; Maziarz RT; Savani BN; Shah AJ; Shah N; Sorror ML; Wood WA; Majhail NS
Biol Blood Marrow Transplant; 2014 Apr; 20(4):587-92. PubMed ID: 24388803
[TBL] [Abstract][Full Text] [Related]
4. Predictors of avascular necrosis of bone in long-term survivors of hematopoietic cell transplantation.
Campbell S; Sun CL; Kurian S; Francisco L; Carter A; Kulkarni S; Parker P; Karanes C; Forman SJ; Bhatia S
Cancer; 2009 Sep; 115(18):4127-35. PubMed ID: 19536905
[TBL] [Abstract][Full Text] [Related]
5. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
Modi A; Rybicki L; Majhail NS; Mossad SB
Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
[TBL] [Abstract][Full Text] [Related]
6. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM).
Socié G; Cahn JY; Carmelo J; Vernant JP; Jouet JP; Ifrah N; Milpied N; Michallet M; Lioure B; Pico JL; Witz F; Molina L; Fischer A; Bardou VJ; Gluckman E; Reiffers J
Br J Haematol; 1997 Jun; 97(4):865-70. PubMed ID: 9217190
[TBL] [Abstract][Full Text] [Related]
7. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
[TBL] [Abstract][Full Text] [Related]
8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
McAvoy S; Baker KS; Mulrooney D; Blaes A; Arora M; Burns LJ; Majhail NS
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1231-6. PubMed ID: 20302963
[TBL] [Abstract][Full Text] [Related]
10. Reduced-Intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin for Hematopoietic Cell Transplantation from Unrelated or Haploidentical Family Donors in Patients with Acute Myeloid Leukemia in Remission.
Lee KH; Lee JH; Lee JH; Kim DY; Park HS; Choi EJ; Ko SH; Seol M; Lee YS; Kang YA; Jeon M; Baek S; Kang YL; Kim SH; Yun SC; Kim H; Jo JC; Choi Y; Joo YD; Lim SN
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1555-1566. PubMed ID: 28552421
[TBL] [Abstract][Full Text] [Related]
11. Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.
Miller HK; Braun TM; Stillwell T; Harris AC; Choi S; Connelly J; Couriel D; Goldstein S; Kitko CL; Magenau J; Pawarode A; Reddy P; Riwes M; Yanik GA; Levine JE
Biol Blood Marrow Transplant; 2017 Mar; 23(3):522-528. PubMed ID: 28017733
[TBL] [Abstract][Full Text] [Related]
12. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
[TBL] [Abstract][Full Text] [Related]
13. Impact of graft-versus-host disease on allogeneic hematopoietic cell transplantation for adult T cell leukemia-lymphoma focusing on preconditioning regimens: nationwide retrospective study.
Ishida T; Hishizawa M; Kato K; Tanosaki R; Fukuda T; Takatsuka Y; Eto T; Miyazaki Y; Hidaka M; Uike N; Miyamoto T; Tsudo M; Sakamaki H; Morishima Y; Suzuki R; Utsunomiya A
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1731-9. PubMed ID: 24090597
[TBL] [Abstract][Full Text] [Related]
14. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for chronic graft-versus-host disease after allogeneic stem cell transplantation in children.
Kondo M; Kojima S; Horibe K; Kato K; Matsuyama T
Bone Marrow Transplant; 2001 Apr; 27(7):727-30. PubMed ID: 11360113
[TBL] [Abstract][Full Text] [Related]
16. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study.
Kanda J; Hishizawa M; Utsunomiya A; Taniguchi S; Eto T; Moriuchi Y; Tanosaki R; Kawano F; Miyazaki Y; Masuda M; Nagafuji K; Hara M; Takanashi M; Kai S; Atsuta Y; Suzuki R; Kawase T; Matsuo K; Nagamura-Inoue T; Kato S; Sakamaki H; Morishima Y; Okamura J; Ichinohe T; Uchiyama T
Blood; 2012 Mar; 119(9):2141-8. PubMed ID: 22234682
[TBL] [Abstract][Full Text] [Related]
17. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
18. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
[TBL] [Abstract][Full Text] [Related]
19. Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation.
Schulte CM; Beelen DW
Transplantation; 2005 Jun; 79(12):1748-55. PubMed ID: 15973180
[TBL] [Abstract][Full Text] [Related]
20. Post-Transplant Cyclophosphamide Combined with Anti-Thymocyte Globulin as Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Alanazi W; Chen S; Lipton JH; Kim DD; Viswabandya A; Kumar R; Lam W; Law AD; Al-Shaibani Z; Mattsson J; Michelis FV
Acta Haematol; 2021; 144(1):66-73. PubMed ID: 32428903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
